Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Q3 Revenues Increase 37 Percent

NEW YORK (GenomeWeb) – NeoGenomics today reported a 37 percent year-over-year increase in its third quarter revenues.

For the three months ended Sept. 30, the Ft. Meyers, Fla.-based cancer genetics testing services company said that revenues rose to $23.2 million from $16.9 million in the year-ago quarter. Revenues from PathLogic, which NeoGenomics acquired in July, accounted for $2.4 million of the revenue growth, it said. Excluding PathLogic, revenues were up 23 percent year over year, driven by a 33 percent uptick in test volume.

NeoGenomics recorded a net loss of $291,000, or $.01 per share, for Q3 2014, compared to a profit of $900,000, or $.02 per share, a year ago.

Its R&D costs increased sharply to more than $1 million during the recently completed quarter, compared to $340,000 a year ago. Its SG&A expenses were up 40 percent to $9.4 million from $6.7 million.

The firm ended the quarter with $34.4 million in cash and cash equivalents. In August, NeoGenomics raised $34.5 million in a public offering.

"As we exit the third quarter, we are in the strongest position we have ever been in," NeoGenomics Chairman and CEO Douglas VanOort said in a statement. "Momentum is accelerating throughout the business, and our recent equity raise has given us a strong balance sheet and greater strategic flexibility to achieve our long-term objectives. We are pleased with our progress in the third quarter and believe we are well-positioned for sustained future growth and success."

The company guided fourth quarter revenues to a range of $23 million to $24.5 million and EPS to a range of break-even to $.01.

It adjusted its guidance for full-year 2014 to between $85 million and $86.5 million in revenues and between $.01 and $.03 in EPS. NeoGenomics had previously provided guidance in the range of $83 million to $86 million in revenues and break-even to $.03 in EPS.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.